10-K - Launch One Acquisition Corp. (0002015502) (Filer)

425 - Launch One Acquisition Corp. (0002015502) (Subject)

8-K - Launch One Acquisition Corp. (0002015502) (Filer)

SCHEDULE 13G/A - Launch One Acquisition Corp. (0002015502) (Subject)

SCHEDULE 13G/A - Launch One Acquisition Corp. (0002015502) (Subject)

SCHEDULE 13G/A - Launch One Acquisition Corp. (0002015502) (Subject)

SCHEDULE 13G - Launch One Acquisition Corp. (0002015502) (Subject)

SCHEDULE 13G - Launch One Acquisition Corp. (0002015502) (Subject)

425 - Launch One Acquisition Corp. (0002015502) (Subject)

10-Q - Launch One Acquisition Corp. (0002015502) (Filer)

HAIFA, Israel, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, today announced that it has been granted two new U.S. patents that further expand and strengthen its global intellectual property portfolio supporting its proprietary Mitochondrial Augmentation Therapy (MAT) platform. The newly granted patents cover mitochondrial augmentation therapy for primary mitochondrial diseases and mitochondrial augmentation therapy for renal diseases, providing extended protection for Minovia's core platform technology. Corresponding

HAIFA, Israel, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that data collected by research teams at Memorial Sloan Kettering Cancer Center (MSK) and Shaare Zedek Medical Center (SZMC) featuring the Company's mitochondrial augmentation technology in myelodysplastic syndrome (MDS) will be presented at the 67th American Society of Hematology's (ASH) Annual Meeting and Exposition on December 6-9, 2025 in Orlando, FL. The data will be featured in an oral presentation to be held on Saturday, Dec 6, 2PM ET (abs25-

HAIFA, Israel, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to the Company's lead investigational compound, MNV-201 for Myelodysplastic Syndrome (MDS), a serious age-related hematopoietic disease. This designation is in addition to the existing FDA Fast Track Designation in MDS, as well as both Fast Track and Rare Pediatric Disease Designations for MNV-201 in the treatment of Pearson Syndrome. "We continue to receive

HAIFA, Israel, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to the Company's lead investigational compound, MNV-201 for Myelodysplastic Syndrome (MDS), a serious age-related hematopoietic disease. This designation is in addition to the existing FDA Fast Track and Rare Pediatric Disease Designations for MNV-201 in the treatment of Pearson Syndrome, an ultra-rare and life-threatening mitochondrial disorder affecting chil

HAIFA, Israel, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that it has been chosen to receive a $350,000 grant from Countdown for a Cure for a research proposal related to the development of novel mitochondrial blood-based biomarkers. Minovia Chief Scientific Officer Dr. Noa Sher, commented, "We are grateful to the Countdown for a Cure Foundation, whose funds are expected to be instrumental in our advancing development of blood-based functional mitochondrial biomarkers. These biomarkers will enab

HAIFA, Israel, July 24, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces positive interim results of the ongoing Phase 2 trial of the Company's lead investigational compound MNV-201 in Pearson Syndrome, a fatal pediatric mitochondrial disease characterized by sideroblastic anemia (a disorder causing abnormal red blood cell development), failure to thrive and exocrine pancreas dysfunction. The interim analysis was presented at the United Mitochondrial Disease Foundation (UMDF) Annual Meeting on June 20, 2025. The analysis

Haifa, ISRAEL, June 30, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to the Company's lead investigational compound, MNV-201. The FDA has also granted Rare Pediatric Disease Designation to MNV-201, which is in Phase 2 clinical trials for the treatment of Pearson Syndrome, an ultra-rare and life-threatening mitochondrial disorder affecting children. "Both Fast Track Designation and Pediatric Rare Disease Designation are critical m

HAIFA, Israel, and GEORGE TOWN, Cayman Islands, June 25, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. ("Minovia" or the "Company"), a clinical-stage biotechnology company developing what it believes to be first-in-class therapies to treat mitochondrial diseases and combat age-related decline, and Launch One Acquisition Corp. (NASDAQ:LPAA, "Launch One")), a special purpose acquisition company focused on healthcare innovation, announce entering into a definitive business combination agreement (the "Business Combination Agreement").    Transaction highlights: The proposed business combination (the "Business Combination") will create a publicly traded, clinical-stage biotechnology

SC 13G - Launch One Acquisition Corp. (0002015502) (Subject)

SC 13G - Launch One Acquisition Corp. (0002015502) (Subject)

SC 13G - Launch One Acquisition Corp. (0002015502) (Subject)

SC 13G/A - Launch One Acquisition Corp. (0002015502) (Subject)

SC 13G - Launch One Acquisition Corp. (0002015502) (Subject)